Atria Wealth Solutions Inc. Makes New Investment in Vaxcyte, Inc. $PCVX

Key Points

• Atria Wealth Solutions Inc. has acquired 7,540 shares of Vaxcyte, Inc. (NASDAQ:PCVX) valued at approximately $245,000 during the second quarter.
• Several institutional investors have significantly increased their holdings in Vaxcyte, with 96.78% of the stock now owned by institutional investors.
• The current consensus rating for Vaxcyte is a "Moderate Buy" with a target price of $106.25, despite the company's recent earnings miss.

Atria Wealth Solutions Inc. acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 7,540 shares of the company's stock, valued at approximately $245,000.

Several other institutional investors also recently modified their holdings of PCVX. RA Capital Management L.P. grew its holdings in shares of Vaxcyte by 40.3% in the first quarter. RA Capital Management L.P. now owns 12,189,149 shares of the company's stock valued at $460,262,000 after acquiring an additional 3,499,959 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Vaxcyte by 44.4% in the first quarter. Wellington Management Group LLP now owns 6,416,930 shares of the company's stock valued at $242,303,000 after acquiring an additional 1,972,918 shares in the last quarter. Baker BROS. Advisors LP grew its holdings in shares of Vaxcyte by 1,211.0% in the first quarter. Baker BROS. Advisors LP now owns 640,885 shares of the company's stock valued at $24,200,000 after acquiring an additional 592,000 shares in the last quarter. Nuveen LLC bought a new position in shares of Vaxcyte in the first quarter valued at approximately $20,988,000. Finally, Fiera Capital Corp bought a new position in shares of Vaxcyte in the first quarter valued at approximately $13,563,000. 96.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on PCVX. The Goldman Sachs Group began coverage on Vaxcyte in a report on Friday, September 12th. They issued a "neutral" rating and a $38.00 target price for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Vaxcyte in a report on Tuesday, October 14th. Finally, Cowen reissued a "buy" rating on shares of Vaxcyte in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Vaxcyte currently has a consensus rating of "Moderate Buy" and a consensus target price of $106.25.

Vaxcyte Trading Up 0.4%

Shares of NASDAQ PCVX opened at $42.51 on Thursday. The stock has a fifty day simple moving average of $35.33 and a two-hundred day simple moving average of $33.94. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $116.00. The firm has a market cap of $5.52 billion, a price-to-earnings ratio of -10.34 and a beta of 1.12.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period in the previous year, the firm posted ($1.10) earnings per share. Analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.